Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 4Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Specimen Handling 76Bevacizumab 66Drug Therapy 64Cisplatin 64Carboplatin 63Magnetic Resonance Spectroscopy 59Radiotherapy 57pembrolizumab 54Gemcitabine 54Cyclophosphamide 54Capecitabine 51Oxaliplatin 50toripalimab 44Paclitaxel 41tislelizumab 40Standard of Care 39fludarabine 36Fluorouracil 35Injections 34Biopsy 34venetoclax 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 29Surgical Procedures, Operative 28Nivolumab 28Irinotecan 27Docetaxel 27Dexamethasone 27Leucovorin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ravulizumab × 1 year × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡